410 filings
Page 2 of 21
8-K
k2fbg6qzoz3n g8htjb
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
kvk67
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
b2g2rtvjhnqroc r0p23
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
sj1lw8x645iiu1d
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
425
x7aslojp9d hgq9
30 Oct 23
Business combination disclosure
4:42pm
8-K
3gyq1t
30 Oct 23
Other Events
8:25am
EFFECT
4n25exw
11 Oct 23
Notice of effectiveness
12:15am
8-K
vl80hyie a757
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
4fqxujg
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
2dhyio8wc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
CORRESP
x8p33vn8c164pjs0ae
6 Oct 23
Correspondence with SEC
12:00am
UPLOAD
3kqs9
4 Oct 23
Letter from SEC
12:00am
S-4
1fg17sw0t3k 8vk
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
DEFA14A
vh3ltulz lq8p88rz
31 Aug 23
Additional proxy soliciting materials
5:25pm
8-K
kad3idojv4fx7
31 Aug 23
Other Events
5:25pm
425
3eju5i bhx
31 Aug 23
Business combination disclosure
8:03am
8-K
ofkpm
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
croez3
14 Aug 23
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023
7:48am